Geptanolimab  (Synonyms: Genolimzumab; APL-501; CBT-501; GB-226)

Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer^[1].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

PDCD1/PD-1/CD279

Geptanolimab (CBT-501) has highly specific binding to PD-1 of human (K_D=505 pM) and cynomolgus (K_D=7.2 nM)^[1].
Geptanolimab enhances human T-cell activation in the Mix Lymphocyte Reaction (MLR), increasing release of IL-2 and INF-γ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Geptanolimab (ip; once every two weeks, for 6 weeks; mice with MC38 syngeneic tumor models) has anti-tumor activity and tumor inhibition rate reached 83%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

5133  [NCBI]

Q15116

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.14 kDa

2348469-43-0

Liquid

Colorless to light yellow

[Geptanolimab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Flow cytometric analysis of 1X10⁶ 10 ng/mL PMA and 1 μg/mL Ionomycin co-stimulated Jurkat cells(24h) with Geptanolimab (HY-P99639, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Qing Z, et, al. Activity of CBT-501, a novel humanized anti-PD-1 antibody, in a humanized genetically engineered mouse model of colon carcinoma. Journal of Clinical Oncology. 2017;35 (7_suppl):108-108.